How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis

Closed for comments This consultation ended on at   Request commenting lead permission

1 Purpose of this document

NICE's early value assessment of digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis recommends that more evidence is generated while the following technologies are being used in the NHS:

  • getUBetter

  • Good Boost

  • Hinge Health

  • Joint Academy

  • Phio Engage

  • re.flex

  • Thrive

  • TrackActiveMe.

Pathway Through Arthritis can only be used in research and is not covered in this plan.

This plan outlines the evidence gaps and what data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence. Evidence generated through other study approaches will also be considered.

The companies are responsible for ensuring that data collection and analysis takes place.

NICE will withdraw the guidance if the companies do not meet the conditions in section 4 on monitoring.

After the end of the evidence generation period (3 years), the companies should submit the evidence to NICE in a format that can be used for decision making. NICE will review all the evidence and assess if the technologies can be routinely adopted in the NHS.